A detailed history of Royce & Associates LP transactions in Bridge Bio Pharma, Inc. stock. As of the latest transaction made, Royce & Associates LP holds 232,923 shares of BBIO stock, worth $15.5 Million. This represents 0.13% of its overall portfolio holdings.

Number of Shares
232,923
Previous 222,305 4.78%
Holding current value
$15.5 Million
Previous $9.6 Million 26.03%
% of portfolio
0.13%
Previous 0.1%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Nov 12, 2025

BUY
$42.78 - $54.29 $454,238 - $576,451
10,618 Added 4.78%
232,923 $12.1 Million
Q2 2025

Aug 11, 2025

BUY
$30.14 - $45.12 $919,963 - $1.38 Million
30,523 Added 15.92%
222,305 $9.6 Million
Q1 2025

May 06, 2025

BUY
$28.12 - $37.59 $1.32 Million - $1.77 Million
46,994 Added 32.46%
191,782 $6.63 Million
Q4 2024

Feb 10, 2025

BUY
$22.35 - $29.5 $510,317 - $673,573
22,833 Added 18.72%
144,788 $3.97 Million
Q3 2024

Nov 06, 2024

BUY
$23.91 - $31.3 $2.92 Million - $3.82 Million
121,955 New
121,955 $3.1 Million

Others Institutions Holding BBIO

About BridgeBio Pharma, Inc.


  • Ticker BBIO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 148,246,000
  • Market Cap $9.84B
  • Description
  • BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabili...
More about BBIO
Track This Portfolio

Track Royce & Associates LP Portfolio

Follow Royce & Associates LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Royce & Associates LP, based on Form 13F filings with the SEC.

News

Stay updated on Royce & Associates LP with notifications on news.